Athira Pharma, Inc. (NASDAQ:ATHA) Short Interest Down 18.5% in November

Athira Pharma, Inc. (NASDAQ:ATHA) was the recipient of a large decline in short interest in November. As of November 30th, there was short interest totalling 1,810,000 shares, a decline of 18.5% from the November 15th total of 2,220,000 shares. Currently, 5.1% of the shares of the stock are short sold. Based on an average daily volume of 4,750,000 shares, the short-interest ratio is currently 0.4 days.

Institutional Investors Weigh In On Athira Pharma

A number of hedge funds have recently added to or reduced their stakes in the business. American Century Companies Inc. grew its holdings in shares of Athira Pharma by 9.4% during the second quarter. American Century Companies Inc. now owns 38,940 shares of the company’s stock worth $103,000 after purchasing an additional 3,333 shares during the last quarter. Renaissance Technologies LLC lifted its position in Athira Pharma by 3.5% during the 2nd quarter. Renaissance Technologies LLC now owns 271,488 shares of the company’s stock worth $719,000 after acquiring an additional 9,164 shares during the period. Rothschild Investment LLC purchased a new position in shares of Athira Pharma in the 2nd quarter valued at approximately $34,000. XTX Topco Ltd acquired a new position in shares of Athira Pharma in the second quarter valued at approximately $60,000. Finally, Forefront Analytics LLC raised its stake in shares of Athira Pharma by 126.0% during the second quarter. Forefront Analytics LLC now owns 46,595 shares of the company’s stock worth $123,000 after purchasing an additional 25,979 shares during the last quarter. 57.12% of the stock is currently owned by institutional investors and hedge funds.

Athira Pharma Trading Up 0.5 %

NASDAQ ATHA traded up $0.00 on Friday, hitting $0.58. 373,474 shares of the company’s stock traded hands, compared to its average volume of 1,583,835. The firm’s 50-day moving average price is $0.58 and its two-hundred day moving average price is $1.71. The firm has a market capitalization of $22.62 million, a PE ratio of -0.21 and a beta of 2.99. Athira Pharma has a 1-year low of $0.41 and a 1-year high of $4.30.

Athira Pharma (NASDAQ:ATHA) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.75) EPS for the quarter, beating the consensus estimate of ($0.80) by $0.05. On average, research analysts anticipate that Athira Pharma will post -2.35 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have issued reports on ATHA. JMP Securities lowered Athira Pharma from an “outperform” rating to a “market perform” rating in a research note on Wednesday, September 4th. Rodman & Renshaw downgraded Athira Pharma from a “buy” rating to a “neutral” rating in a report on Wednesday, September 4th. BTIG Research lowered Athira Pharma from a “buy” rating to a “neutral” rating in a report on Wednesday, September 4th. Finally, Mizuho cut shares of Athira Pharma from an “outperform” rating to a “neutral” rating and cut their target price for the company from $5.00 to $0.50 in a research note on Thursday, September 19th.

Athira Pharma Company Profile

Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.